In a recent article on CNBC.com, Cramer added new stocks to his Covid-19 Index.
Cramer dropped two health-based stocks and one packaged foods company to make room for two cloud-based names and one gold business. VMware (NYSE: VMW), Fastly (NYSE: FLSY) and Newmont Mining (NYSE: NEM) were substituted for Baxter International (NYSE:BAX) , GlaxoSmithKline (NYSE: GSK) and Kellogg (NYSE: K).
The biggest winners on Crammer’s list – Zoom Video (NASDAQ: ZM), Spotify (NYSE: SPOT) Zscaler (NASDAQ: ZS), DocuSign (NASDAQ: DOCU), Etsy (NASDAQ: ETSY), The Trade Desk (NASDAQ: TTD), Livongo Health (NASDAQ: LVGO), Square (NYSE: SQ), Peloton(NASDAQ: PTON) and Cloudflare (NYSE: NET) – are among the top plays in the stay-at-home economy.
“As the pandemic flares up again, get ready after the industrial rotation ends. It’s time to circle back to the blue-chip Covid stocks that are still way off their highs. That’s what offers the best risk-reward,” he said. “I love a rotation. They throw out the good, they buy the bad and then they change their mind two days later.”
Here is another under the radar CAR-T and cell-based technology company with game changing technology that has huge potential upside during the COVID-19 Pandemic
Avalon GloboCare Corp. (NASDAQ: AVCO) a leader in cell-based technology, is launching two major clinical trials to test its blood filtration technology to combat ‘cytokine storms’ induced in some COVID-19 patients and nasal spray vaccine to prevent COVID-19. A major question is how long immunity will last, Jin pointed out. “We see our vaccine candidate as a complement to any injectable vaccines in clinical trials, because it could provide first-line immune protection at the virus’s entrance site,” he added. Avalon’s vaccine has the potential to compliment NASDAQ (MRNA) Moderna and NYSE (PFE) vaccines, as well as penetrate emerging economies with its low storage and administration costs.
(Fortune Business https://www.globenewswire.com/news-release/2020/04/22/2020118/0/en/COVID-19-Vaccine-Addressable-Market-to-Grow-Considerably-Sustained-Efforts-towards-Containing-the-Spread-of-the-Coronavirus-by-Governments-and-Global-Bodies-to-Boost-the-Market-For.html
As a result, the race for vaccine and treatments to contain the COVID-19 outbreak has gotten even more intensified and is reshaping the COVID-19 vaccine-addressable market trends. According to the vaccines market report published before the coronavirus pandemic, the value of the vaccines market was at USD 41.6 billion in 2018 and was expected to reach USD 93.08 billion by 2026 at a CAGR of 10.7) Avalon Globocare currently trades at $1.16 and approximately a 95 million dollar market cap if they can capture even 1% of the growing vaccine market over the next couple of years you do the math.
Have you ever herd of S-Layer technology being used in Vaccinations?
Avalon GloboCare Corp. (NASDAQ: AVCO) has partnered with Uwe B. Sleytr, a world-renowned scientist and pioneer in nanobiotechnology and S-layer technology, at Vienna’s UNRLS. S-layer proteins are naturally occurring proteins on the surface of many bacteria, and the technology is based on the repetitive protein structures that make up the outer surface of microbial cells. S-layer protein materials can be induced to self-assemble into spherical 3D, crystal structures around a passive, scaffold material, resulting in particles that mimic the dimensions and structure of a pathogenic virus.
Avalon and BOKU are establishing a state-of-the-art research facility, the Christian Doppler Laboratory, located on the BOKU campus in Vienna, Austria, under the scientific leadership of Professor Eva-Kathrin Ehmoser, the Head of BOKU’s Institute for Synthetic Bioarchitectures and Professor Uwe Sleytr, a member of the Austrian Academy of Sciences. In connection with the new facility, Avalon and BOKU have signed a Memorandum of Understanding (MOU) to jointly apply for a matching research grant from the prestigious Christian Doppler Laboratory Foundation.
“We are excited and motivated to join forces with the researchers at BOKU to drive innovation. We have already begun a collaboration on the mucosal SARS-CoV-2 vaccine and are moving quickly to establish additional joint research endeavors to bring about innovative technologies and new medicines to patients,” said Dr. Jin.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics. Avalon GloboCare, is a young, $100 million market cap company that has arguably some of the brightest minds in cell-based technology. This small cap biotechnology company is working towards the goal of changing the way we fight the devastating affects of diseases that relentlessly attack our immune systems by using our own bodies against us. In the first quarter of 2020, Avalon GloboCare successfully completed a phase 1 first-in-human clinical study of AVA-001 in China for the treatment of relapsed refractory B cell acute lymphoblastic leukemia (R/R B-ALL). 90% of R/R B-ALL patients achieved complete remission with one dose and within one month of treatment, and then proceeded to a curative-intent allogeneic bone marrow transplant. With more upcoming catalysts in Q4 2020 and early 2021, it is safe to say that there is a large potential upside in AVCO’s stock that currently trades at only $1.17. The company has been well capitalized to date and has very clean cap table relative to its industry peers making it an attractive investment.
Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.